



CareDx Testing Solutions for Kidney Transplant Recipients

- **AlloSure Kidney** is the most broadly utilized dd-cfDNA solution in kidney transplantation, clinically validated in the pivotal **DART Study**, published in JASN [1], as well as the largest-in-class real world study **ADMIRAL**, published in Kidney International [2]. Combined, these studies enrolled **1,400 patients undergoing dd-cfDNA testing**, representative of a large and diverse population of kidney transplant recipients.
- **AlloSure Values Yield Clinically Actionable Signals Across the Spectrum of Kidney Transplants:** Elevations in AlloSure track **with graft injury**, including ABMR and TCMR, while low values confer **high negative predictive value** [2, 3, 4], helping clinicians assess the need for allograft biopsy.
- AlloSure Kidney is validated in both **for-cause and surveillance settings** [2, 3] across clinically and immunologically complex sub-populations. These include **re-transplant recipients** [5], **DSA-positive patients** [4, 6], and **pediatric patients** [7, 8].
- **AlloSure Kidney Has Demonstrated Clinical Utility in the Surveillance of Allograft Injury:** Surveillance with AlloSure (AlloSure Routine Testing Schedule; ARTS) provides a framework for dd-cfDNA surveillance at clinically relevant immunologic transition points [1, 9]. ARTS has been implemented at centers throughout the country [2, 10]. AlloSure has demonstrated predictive/prognostic utility in risk stratifying patients with borderline and low-grade TCMR [11] as well as in identifying patients at risk for eGFR decline and development of de novo DSA [2, 12].
- **AlloSure Kidney is Valuable in Monitoring Clinical Course and Treatment Response in Rejection:** Serial surveillance to determine patient-specific baseline measurements and monitor change over time can help **identify evolving injury** [2, 13] and help **assess response to therapy** [3].
- **We Anticipate the CareDx Pipeline Will Soon Include Multimodality Testing**
Gene Expression Profiling with AlloMap Kidney, based on the broadly utilized AlloMap Heart, included in the 2010 ISHLT guidelines, will help clinicians define immune quiescence and complement the graft injury detection of AlloSure Kidney to bring multimodality surveillance into the clinic [14, 15].

[A full bibliography is linked here.](#)